MEA DPA Hypoxic Event Reductions

April 30, 2026 updated by: Jean-Louis Horn, Stanford University

Minimizing Deoxygenation Events During Anesthesia With a Novel Distal Pharyngeal Airway

The goal of the study is to compare deoxygenation events during anesthesia induction and mask ventilation when using standard oral pharyngeal airways or the novel distal pharyngeal airway.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Withdrawn

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This prospective RCT will study adult patients who are determined to be at high risk for deoxygenation events during induction of general anesthesia. The study will randomize patients for use of a novel airway device (distal pharyngeal airway) versus standard oral pharyngeal airway during general anesthetic induction and measure differences in severity and duration of desaturation (hypoxic) events. The premise is the new novel device will reduce hypoxic events, improving patient safety and reducing airway complications. This is critically important as hypoxic events can have significant consequences. Providing a device that minimizes hypoxic events could impact patient safety positively. Additional measurements will include reduction in unanticipated patient admissions from airway complications with DPA use.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient presenting for surgery at main Stanford Hospital
  • Over 18 years old
  • ASA Class II, III, IV
  • High risk for hypoxic events during intubation based on their past medical history
  • BMI >35
  • Likelihood of obstructive sleep apnea utilizing the STOP-BANG questionnaire
  • History of diagnosed sleep apnea
  • History of difficult intubation
  • Prior need for two-handed mask ventilation
  • Requiring general anesthesia with endotracheal intubation for surgery

Exclusion Criteria:

  • Altered mental status
  • Anesthesia technique includes rapid sequence or modified rapid sequence intubation
  • Poorly controlled gastroesophageal reflux

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Novel DPA device
Assess duration and severity of deoxygenation events with DPA use during anesthetic induction and mask ventilation.
Device: DPA
Anesthesiologist will use novel DPA device post anesthetic induction to assist in bag mask ventilation prior to endotracheal tube placement.
Active Comparator: Standard OPA device
Assess duration and severity of deoxygenation events with OPA use during anesthetic induction and mask ventilation.
Device: OPA
Anesthesiologist will use standard OPA device post anesthetic induction to assist in bag mask ventilation prior to endotracheal tube placement.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number of participants with clinically significant hypoxia SpO2 < 92
Time Frame: Post-treatment recorded intra-operatively (up to 24 hours)
This outcome will be compared between two groups.
Post-treatment recorded intra-operatively (up to 24 hours)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of additional airway maneuvers used during bag-mask ventilation with the MEA DPA and OPA during induction of general anesthesia
Time Frame: Post-treatment recorded intra-operatively (up to 24 hours)
Post-treatment recorded intra-operatively (up to 24 hours)
Determine if additional airway maneuvers are used during bag-mask ventilation with the MEA DPA and OPA during induction of general anesthesia
Time Frame: Post-treatment recorded intra-operatively (up to 24 hours)
The number of supplemental airway interventions that the anesthesiologist must use to be able to ventilate the patient after the OPA or MEA DPA placement will be assessed. These supplemental interventions include chin lifts, jaw thrusts, head repositioning, and asking for additional aid when ventilating the patient. These notes will be compared and confirmed with the recorded induction footage from the cameras. Following data collection, data will be compared to demonstrate if there is a reduction in the need for manual intervention with the MEA DPA compared to a standard airway.
Post-treatment recorded intra-operatively (up to 24 hours)
Change in anesthesia provider satisfaction during anesthetic bag-mask ventilation (positive pressure ventilation)
Time Frame: Immediately post-operatively (up to 24 hours)
Anesthesiologists will be asked if the MEA DPA is easier, harder, or has the same level of difficulty in placement and use as the standard OPA. Following data collection, the differences between the intervention and control group will be compared to demonstrate improved anesthesia provider satisfaction based on ease of placement, use and preferred future usage of MEA DPA.
Immediately post-operatively (up to 24 hours)
Incidence of obstruction for sedated patients arriving in postoperative care with an airway in situ
Time Frame: Immediately post-operatively (up to 24 hours)
PACU nurse will indicate if the MEA DPA correlates with reduced post-operative care unit (PACU) airway manipulation (head repositioning, jaw thrust, increased oxygen flows). Following data collection, the differences between the intervention and control group will be compared to demonstrate preferred use through decreased airway management needs for PACU nurses with the DPA and reduced patient discomfort.
Immediately post-operatively (up to 24 hours)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 24, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 30, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 7, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 7, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 30, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 73525

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings